دواعي استعمال تريتاس بروتكت 10مجم 20 قرص

Ramipril 10 mg tablets, pack of 20 (Sanofi, Egyptian market).

• علاج ارتفاع ضغط الدمالفئة: Adultselectronic medicines compendium (emc)
• Cardiovascular prevention in patients with manifest atherothrombotic cardiovascular disease or diabetes with at least one cardiovascular risk factorالفئة: Adultselectronic medicines compendium (emc)
• Treatment of renal disease (incipient or manifest diabetic glomerular nephropathy; manifest non-diabetic glomerular nephropathy with macroproteinuria >=3 g/day)الفئة: Adultselectronic medicines compendium (emc)
• Treatment of symptomatic heart failureالفئة: Adultselectronic medicines compendium (emc)
• Secondary prevention after acute myocardial infarction with clinical signs of heart failure (started >48 hours after MI)الفئة: Adultselectronic medicines compendium (emc)

• Safety profile includes persistent dry cough and reactions due to hypotension; serious reactions include angioedema, hyperkalaemia, renal or hepatic impairment, pancreatitis, severe skin reactions and neutropenia/agranulocytosis. Headache and dizziness are listed among common reactions.نشرة دولية لنفس التركيبة · electronic medicines compendium (emc)

• Hypersensitivity to ramipril, any excipient or any other ACE inhibitor; history of angioedema (hereditary, idiopathic or previous ACE inhibitor/AIIRA angioedema).نشرة دولية لنفس التركيبة · electronic medicines compendium (emc)
• Concomitant sacubitril/valsartan; extracorporeal treatments bringing blood into contact with negatively charged surfaces.نشرة دولية لنفس التركيبة · electronic medicines compendium (emc)
• Significant bilateral renal artery stenosis or stenosis in a single functioning kidney; hypotensive or haemodynamically unstable states; second and third trimesters of pregnancy.نشرة دولية لنفس التركيبة · electronic medicines compendium (emc)
• Aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m2).نشرة دولية لنفس التركيبة · electronic medicines compendium (emc)

• Risk of marked hypotension in patients with a strongly activated renin-angiotensin-aldosterone system (e.g. diuretic-treated, volume/salt depleted, severe hypertension, heart failure); initiate under supervision.نشرة دولية لنفس التركيبة · electronic medicines compendium (emc)
• Angioedema (including intestinal angioedema) may occur; risk increased with mTOR inhibitors, vildagliptin or neprilysin inhibitors; discontinue and treat promptly.نشرة دولية لنفس التركيبة · electronic medicines compendium (emc)
• Hyperkalaemia, hyponatraemia, neutropenia/agranulocytosis and renal function deterioration may occur; persistent dry cough is a known ACE inhibitor effect.نشرة دولية لنفس التركيبة · electronic medicines compendium (emc)

• Potassium salts, heparin, potassium-retaining diuretics, trimethoprim/co-trimoxazole, tacrolimus, ciclosporinHyperkalaemia may occur; close monitoring of serum potassium required.electronic medicines compendium (emc)
• Lithium saltsACE inhibitors may reduce lithium excretion and increase lithium toxicity; monitor lithium levels.electronic medicines compendium (emc)
• NSAIDs and acetylsalicylic acidReduced antihypertensive effect; increased risk of worsening renal function and increased potassium.electronic medicines compendium (emc)
• Antidiabetic agents including insulinHypoglycaemic reactions may occur; blood glucose monitoring recommended.electronic medicines compendium (emc)

• Not recommended because of insufficient information; alternatives with better established safety are preferred, especially for newborn or preterm infants.نشرة دولية لنفس التركيبة · electronic medicines compendium (emc)

• Monitor renal function and serum potassium (especially at initiation and with diuretics); monitor sodium in at-risk patients; white cell count monitoring may be needed.نشرة دولية لنفس التركيبة · electronic medicines compendium (emc)

• راميبريل: طليعة دواء يتحلل إلى راميبريلات الذي يثبط الإنزيم المحول للأنجيوتنسين فيقلل تكوين الأنجيوتنسين II وإفراز الألدوستيرون.مثبط الإنزيم المحول للأنجيوتنسين